Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade

• Published in: Cancer drug resistance Vol. 3; no. 4; pp. 832 - 853
• Main Authors: Lotsberg, Maria L, Rayford, Austin, Thiery, Jean Paul, Belleggia, Giuliana, D'Mello Peters, Stacey, Lorens, James B, Chouaib, Salem, Terry, Stephane, Engelsen, Agnete S T
• Format: Journal Article
• Language: English
• Published: United States OAE Publishing Inc 01-01-2020
• Subjects: Review; intrinsic and extrinsic mechanisms of resistance to immune checkpoint blockade; epithelial-mesenchymal plasticity; immune evasion; tumor immune microenvironment; Epithelial-to-mesenchymal transition; therapeutic opportunity
• ISSN: 2578-532X; 2578-532X
• DOI: 10.20517/cdr.2020.41

Epithelial-mesenchymal plasticity (EMP) of cancer cells contributes to cancer cell heterogeneity, and it is well established that EMP is a critical determinant of acquired resistance to cancer treatment modalities including radiation therapy, chemotherapy, and targeted therapies. Here, we aimed to explore how EMP contributes to cancer cell camouflage, allowing an ever-changing population of cancer cells to pass under the radar of our immune system and consequently compromise the effect of immune checkpoint blockade therapies. The ultimate clinical benefit of any combination regimen is evidenced by the sum of the drug-induced alterations observed in the variety of cellular populations composing the tumor immune microenvironment. The finely-tuned molecular crosstalk between cancer and immune cells remains to be fully elucidated, particularly for the spectrum of malignant cells along the epithelial to mesenchymal axis. High-dimensional single cell analyses of specimens collected in ongoing clinical studies is becoming a key contributor to our understanding of these interactions. This review will explore to what extent targeting EMP in combination with immune checkpoint inhibition represents a promising therapeutic avenue within the overarching strategy to reactivate a halting cancer-immunity cycle and establish a robust host immune response against cancer cells. Therapeutic strategies currently in clinical development will be discussed.